Related Experiment Video
Updated: Jul 3, 2026
Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A
1Northwestern University Feinberg School of Medicine, Department of Surgery, Division of Gastrointestinal & Endocrine Surgery, Chicago, Illinois 60611-2908, USA.
Insights
Parathyroidectomy (PTX) is cost-effective for asymptomatic primary hyperparathyroidism (PHPT) patients over 50 with a life expectancy of at least 5-6.5 years. For shorter prognoses, observation is the preferred strategy.
Area of Science:
- Endocrinology
- Health Economics
- Surgical Decision Making
Background:
- National Institutes of Health guidelines recommend parathyroidectomy (PTX) for primary hyperparathyroidism (PHPT) in patients younger than 50.
- The optimal management strategy for asymptomatic PHPT patients over 50 remains debated.
Purpose of the Study:
- To conduct a cost-effectiveness analysis comparing PTX, observation, and pharmacologic treatment for asymptomatic PHPT in patients over 50.
- To determine the optimal strategy based on life expectancy.
Main Methods:
- A Markov model was utilized to compare treatment strategies from a third-party payer perspective.
- Quality-adjusted life-years (QALYs) were calculated, and future costs/QALYs were discounted at 3%.
- Threshold and multivariate sensitivity analyses (Monte Carlo simulation) were performed.
Main Results:
- Parathyroidectomy (PTX) was the optimal strategy for life expectancies of 5 years (outpatient) and 6.5 years (inpatient).
- Observational management was most cost-effective for patients with shorter life expectancies.
- Pharmacologic treatment was not found to be optimal at any life expectancy.
Conclusions:
- Parathyroidectomy (PTX) is a cost-effective strategy for many patients over 50 with asymptomatic primary hyperparathyroidism (PHPT).
- The decision for PTX should consider a predicted life expectancy of at least 5-6.5 years.
- Observation is the most cost-effective approach for patients with a life expectancy below these thresholds.
Background:
The National Institutes of Health consensus conference on asymptomatic primary hyperparathyroidism (PHPT) recommended several criteria for parathyroidectomy (PTX), including age <50 years. We hypothesized that a cost-effectiveness analysis would show PTX to be the optimal strategy for asymptomatic patients >50 years of age.
Methods:
A Markov model was constructed comparing operative, observational, and pharmacologic treatments. Costs were estimated from a third-party payer perspective. Outcomes were weighted with utility adjustment factors, yielding quality-adjusted life-years (QALYs). Future costs and QALYs were discounted at 3%. Threshold analysis identified the optimal strategy at life expectancies ranging from 6 months to 75 years. Multivariate sensitivity analysis was completed with Monte Carlo simulation.
Results:
PTX was optimal when life expectancy reached 5 years for outpatient PTX and 6.5 years for inpatient PTX. Observation was the optimal strategy at all shorter life expectancies considered. The pharmacologic treatment strategy was not optimal at any life expectancy.
Conclusion:
PTX is the optimal strategy for many patients with asymptomatic PHPT who are >50 years of age. PTX is cost effective for patients with a predicted life expectancy of 5 years (outpatient) or 6.5 years (inpatient). For patients with a shorter life expectancy, observation is the most cost-effective strategy.
